H
Hans-Ulrich Schildhaus
Researcher at University of Duisburg-Essen
Publications - 143
Citations - 3524
Hans-Ulrich Schildhaus is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 24, co-authored 110 publications receiving 2793 citations. Previous affiliations of Hans-Ulrich Schildhaus include University of Göttingen & University of Cologne.
Papers
More filters
Journal ArticleDOI
A genomics-based classification of human lung tumors
Danila Seidel,Thomas Zander,Lukas C. Heukamp,Martin Peifer,Marc Bos,Lynnette Fernandez-Cuesta,Frauke Leenders,Xin Lu,Sascha Ansén,Masyar Gardizi,Chau Nguyen,Chau Nguyen,Johannes Berg,Prudence A. Russell,Zoe Wainer,Hans-Ulrich Schildhaus,Hans-Ulrich Schildhaus,Toni-Maree Rogers,Benjamin Solomon,William Pao,Scott L. Carter,Gad Getz,D. Neil Hayes,Matthew D. Wilkerson,Erik Thunnissen,William D. Travis,Sven Perner,Gavin M. Wright,Elisabeth Brambilla,Reinhard Buettner,Juergen Wolf,Roman K. Thomas,Franziska Gabler,Ines Wilkening,Christian Mueller,Ilona Dahmen,Roopika Menon,Katharina Koenig,Kerstin Albus,Sabine Merkelbach-Bruse,Jana Fassunke,Katja Schmitz,Helen Kuenstlinger,Michaela Angelika Kleine,Elke Binot,Silvia Querings,Janine Altmueller,Ingelore Boessmann,Peter Nuemberg,Peter M. Schneider,Magdalena Bogus,Alex Soltermann,Holger Moch,Odd Terje Brustugun,Steinar Solberg,Marius Lund-Iversen,Åslaug Helland,Thomas Muley,Hans Hoffmann,Philipp A. Schnabel,Yuan Chen,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Joachim H. Clement,Walter Weder,Joerg Saenger,Erich Stoelben,Corinna Ludwig,Walburga Engel-Riedel,Egbert F. Smit,Danille A. M. Heideman,Peter J.F. Snijders,Lucia Nogova,Martin L. Sos,Christian Mattonet,Karin Toepelt,Matthias Scheffler,Eray Goekkurt,Eray Goekkurt,Rainer Kappes,Stefan Krueger,Kato Kambartel,Dirk Behringer,Wolfgang Schulte,Wolfgang Galetke,Winfried Randerath,Matthias Heldwein,Andreas Schlesinger,Monika Serke,Khosro Hekmat,Konrad Frank,Roland Schnell,Marcel Reiser,Ali-Nuri Huenerlituerkoglu,Stephan Schmitz,Lisa Meffert,Yon-Dschun Ko,Markus Litt-Lampe,Ulrich Gerigk,Rainer Fricke,Benjamin Besse,Christian Brambilla,Sylvie Lantuejoul,Philippe Lorimier,Denis Moro-Sibilot,Federico Cappuzzo,C. Ligorio,Stefania Damiani,John K. Field,Russell Hyde,Pierre Validire,Philippe Girard,Lucia Anna Muscarella,Vito Michele Fazio,Michael Hallek,Jean-Charles Soria,Viktor Achter,Ulrich Lang +118 more
TL;DR: Support is provided for broad implementation of genome-based diagnosis of lung cancer by demonstrating the correlation between lung tumor subtype and its predominant mutations, and the benefit of genetic testing and targeted therapy in these patients.
Journal ArticleDOI
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Eva Wardelmann,Sabine Merkelbach-Bruse,Katharina Pauls,Nadja Thomas,Hans-Ulrich Schildhaus,Thomas Heinicke,Nicola Speidel,Torsten Pietsch,Reinhard Buettner,Daniel Pink,Peter Reichardt,Peter Hohenberger +11 more
TL;DR: The identification of newly acquired KIT mutations in addition to the primary mutation is dependent on the number of tissue samples analyzed and has high implications for further therapeutic strategies.
Journal ArticleDOI
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel,Manfred Dietel,Lukas C. Heukamp,Korinna Jöhrens,Thomas Kirchner,Simone Reu,Josef Rüschoff,Hans-Ulrich Schildhaus,Peter Schirmacher,Markus Tiemann,Arne Warth,Wilko Weichert,Rieke Fischer,Jürgen Wolf,Reinhard Buettner +14 more
TL;DR: The data indicate that carcinoma cells can be reproducibly scored in PD-L1 immunohistochemistry for pulmonary adenocarcinoma and squamous-cell carcinoma and might require specific standardization.
Journal ArticleDOI
Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors
Sandra Ortiz-Cuaran,Matthias Scheffler,Dennis Plenker,llona Dahmen,Andreas H. Scheel,Lynnette Fernandez-Cuesta,Lydia Meder,Christine M. Lovly,Thorsten Persigehl,Sabine Merkelbach-Bruse,Marc Bos,Sebastian Michels,Rieke Fischer,Kerstin Albus,Katharina König,Hans-Ulrich Schildhaus,Jana Fassunke,Michaela Angelika Ihle,Helen Pasternack,Carina Heydt,Christian Becker,Janine Altmüller,Hongbin Ji,Christian Müller,Alexandra Florin,Johannes M. Heuckmann,Peter Nuernberg,Sascha Ansén,Lukas C. Heukamp,Johannes Berg,William Pao,Martin Peifer,Reinhard Buettner,Jürgen Wolf,Roman K. Thomas,Martin L. Sos +35 more
TL;DR: The data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.
Journal ArticleDOI
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung
Hans-Ulrich Schildhaus,Anne M Schultheis,Josef Rüschoff,Elke Binot,Sabine Merkelbach-Bruse,Jana Fassunke,Wolfgang Schulte,Yon-Dschun Ko,Andreas Schlesinger,Marc Bos,Masyar Gardizi,Walburga Engel-Riedel,Michael Brockmann,Monika Serke,UIlrich Gerigk,Khosro Hekmat,Konrad Frank,M. Reiser,Holger Schulz,Stefan Krüger,Erich Stoelben,Thomas Zander,Jürgen Wolf,Reinhard Buettner +23 more
TL;DR: The data suggest that it might be useful to determine MET amplification before EGFR inhibitor treatment to identify possible primary resistance to anti-EGFR treatment, and to select cases that harbor KRAS mutations additionally to MET amplification and, thus, may not benefit from MET inhibition.